Our Development Pipeline


Topical Rapamycin

TMB-002, a proprietary topical rapamycin, is being developed for the treatment of facial angiofibromas (FA) and tuberous sclerosis complex (TSC). Efficacy has been demonstrated in multiple well controlled studies and dozens of published case reports for topical mTOR inhibitors that have been compounded in the past. However, there is no commercial formulation available. TMB-002 is a room temperature stable 1% formulation of rapamycin with a high level of content uniformity. A Phase 2b clinical trial of TMB-002 is currently ongoing, with recruitment expected to be completed by the end of Q3 2021 and, as per protocol, data is expected six months from the date that the last patient was enrolled.

Screen Shot 2021-07-08 at 7.19.39 PM.png

If you are interested in any of Timber’s ongoing clinical research programs, please contact trials@timberpharma.com.